Healthcare / Medical DistributionHKSE
$1.32
-0.13 (-8.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-70.2M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$969M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.3%
↓Gross Margin
15.0%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.5%
FCF CAGR
—
FCF margin
0.0%
FCF / Net income
-0.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.07B · net income $-124.3M · FCF $127000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.07B | $2.07B | $4.57B | $4.71B | $4.12B |
| Net Income | $-124.3M | $-124.3M | $-323.7M | $-255.8M | $-1.37B |
| EBITDA | $-99.8M | $-99.8M | $-308.8M | $-189.2M | $-1.31B |
| EPS | -0.21 | -0.21 | -0.51 | -0.40 | -12.19 |
| Gross Margin | 15.0% | 15.0% | 8.5% | 8.8% | 8.2% |
| Operating Margin | -4.5% | -4.5% | -6.1% | -5.2% | -14.9% |
| Net Margin | -6.0% | -6.0% | -7.1% | -5.4% | -33.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.04 | 0.04 |
| Current Ratio | 1.83 | 1.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $127000.00 | $127000.00 | $-70.2M | $-139.2M | $-193.9M |
| Returns | |||||
| ROE | -13.3% | -13.3% | -26.4% | -15.8% | -74.6% |
| Valuation | |||||
| P/B | 0.85 | 0.85 | 2.64 | 2.58 | 1.14 |
| Growth & Yield | |||||
| Revenue Growth | -54.6% | -54.6% | -3.1% | 14.4% | — |
| EPS Growth | 58.8% | 58.8% | -27.5% | 96.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-66.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.51 → -0.21
Residual
-66.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.